TY - JOUR T1 - Model Based Estimation of the SARS-CoV-2 Immunization Level in Austria and Consequences for Herd Immunity Effects JF - medRxiv DO - 10.1101/2021.03.10.21253251 SP - 2021.03.10.21253251 AU - Martin Bicher AU - Claire Rippinger AU - Günter Schneckenreither AU - Nadine Weibrecht AU - Christoph Urach AU - Melanie Zechmeister AU - Dominik Brunmeir AU - Wolfgang Huf AU - Niki Popper Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/03/12/2021.03.10.21253251.abstract N2 - Several systemic factors indicate, that worldwide herd immunity against COVID-19 will probably not be achieved in 2021. Vaccination programs are limited by availability of doses, the number of people already infected is still too low to have a disease preventing impact and new emerging variants of the virus seem to partially neglect developed antibodies from previous infections. Nevertheless, after one year of COVID-19 observing high numbers of reported cases in most European countries, we might expect that the immunization level should have an impact on the spread of SARS-CoV-2. We used an agent-based simulation model to reproduce the COVID-19 pandemic in Austria to estimate the immunization level of the population as of February 2021. We ran several simulations of an uncontrolled epidemic wave with varying initial immunization scenarios to assess the effect on the effective reproduction number. We also used a classic differential equation SIR-model to cross-validate the simulation model. As of February 2021, 14.7% of the Austrian population has been affected by a SARS-CoV-2 infection which causes a 9% reduction of the effective reproduction number and a 24.7% reduction of the prevalence peak compared to a fully susceptible population. This estimation is now recomputed on a regular basis to publish model based analysis of immunization level in Austria also including the fast growing effects of vaccination programs. This provides substantial information for decision makers to evaluate the necessity of NPI-measures based on the estimated impact of natural and vaccinated immunization.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by the Austrian Research Promotion Agency (FFG) COVID-19 Emergency Call, the Vienna Science and Technology Fund WWTF-COVID-19 Rapid Response Funding, the Medical Scientific Fund of the Mayor of the City of Vienna and the Society for Medical Decision Making (SMDM) COVID-19 Decision Modeling Initiative.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study had no need of any ethics committee approvalAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data for the simulated SARS-CoV-2 seroprevalence level in Austria are publicly available and are updated regularly (see Link 1). Data for estimation of the seroprevalence level were drawn from the official Austrian epidemiological reporting system for SARS-CoV-2 (EMS, see Link 2) and the results from (serological and prevalence) randomized screening studies performed in Austria (see Links 3 and 4). Metadata used for parametrization of the simulation model is found the parameter-tables found in the supplemental of publicly available preprint "Evaluation of Contact-Tracing Policies Against the Spread of SARS-CoV-2 in Austria - An Agent-Based Simulation" (Link 5). http://www.dexhelpp.at/en/immunization_level/ https://covid19-dashboard.ages.at/ https://www.sora.at/nc/news-presse/news/news-einzelansicht/news/covid-19-praevalenz-1006.html https://www.statistik.at/web_de/statistiken/menschen_und_gesellschaft/gesundheit/covid19/index.html https://www.medrxiv.org/content/10.1101/2020.05.12.20098970v4 ER -